CTOs on the Move

Alkermes

www.alkermes.com

 
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.alkermes.com
  • 852 Winter Street
    Waltham, MA USA 02451
  • Phone: +353 1 772 8000

Executives

Name Title Contact Details
Jonathan Brooks
Senior Director, Global Security Profile
John Lamoureux
Senior Director of Information Technology Profile
Mike Legato
Associate Director of Information Technology Applications Profile

Similar Companies

Precision Life Sciences

RESULTS ARE IN OUR DNA Fostering partnerships within the Life Science industry to enable innovation and positive outcomes. CLIENTS JOB SEEKERS Company We Are Precision Life Sciences Precision Life Sciences, a WBE (Woman-Owned Business Enterprise), was ...

DoctorDirectory - IncreaseRx

DoctorDirectory - IncreaseRx is a Asheville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clinuvel

Clinuvel is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ReactDx

Ambulatory Cardiac Monitoring | Mobile Cardiac Telemetry, Holter, Extended Holter & Wireless Event | Implantable Monitoring Service | Helping physicians add quality years to patients lives, ONE patient at a time.

Unum Therapeutics

Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers.   Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.